Literature DB >> 23102615

Clinicopathological factors impact the survival outcome following the resection of combined hepatocellular carcinoma and cholangiocarcinoma.

Anthony Q Yap1, Chao-Long Chen, Chee-Chien Yong, Fang-Ying Kuo, Shih-Ho Wang, Chih-Che Lin, Yueh-Wei Liu, Ting-Lung Lin, Wei-Feng Li, Carlos A Millan, Chih-Chi Wang.   

Abstract

Studies have demonstrated poor survival outcomes for patients with resected combined hepatocellular carcinoma-cholangiocarcinoma tumours (CHCC-CC). Our objectives are to report on our institutional experience regarding the clinico-pathological and prognostic features of CHCC-CC and to compare our results with published series. The clinico-pathological features and outcomes of 11 patients with CHCC-CC who had a complete surgical resection for primary liver cancer were reviewed. There were 8 male and 3 female patients. The overall median age was 61 years. Active hepatitis B and hepatitis C infections were present in 6 (54%) and 2 (18%) patients, respectively. Alcoholism was present in one case. Cirrhosis was present in 8 (72%) cases. There were no causative factors identified in 2 patients with non-cirrhotic livers. The median AFP value was 30.56 ng/ml. A single mass located in the right lobe and a single mass located in the left lobe of the liver was noted in 6 (54%) and 4 (36%) patients, respectively. Bilobar involvement was observed in one case. Major and minor resections were performed in 2 (18%) and 9 (81%) cases, respectively. The median tumour size was 3 cm. Tumours measuring >5 cm were identified in only 2 (18%) cases. The majority of the cases were classified as stage I (54%) and stage II (36%). Four patients died 11-50 months after the surgery. Postoperative tumour recurrences were observed in 5 (45.45%) patients within 4 years of surgical resection. The overall 1- and 3-year survival rates in this series were 80% and 69.3%. Our series demonstrated cases of CHCC-CC with more favourable pathological traits and survival outcomes compared with similar studies.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23102615     DOI: 10.1016/j.suronc.2012.09.003

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  9 in total

1.  Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.

Authors:  Yan-Ming Zhou; Xiao-Feng Zhang; Lu-Peng Wu; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 2.  Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma.

Authors:  Yuichi Sanada; Yujo Kawashita; Satomi Okada; Takashi Azuma; Shigetoshi Matsuo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

3.  Radiomics predict postoperative survival of patients with primary liver cancer with different pathological types.

Authors:  Jiahui Zhang; Xiaoli Wang; Lixia Zhang; Linpeng Yao; Xing Xue; Siying Zhang; Xin Li; Yuanjun Chen; Peipei Pang; Dongdong Sun; Juan Xu; Yanjun Shi; Feng Chen
Journal:  Ann Transl Med       Date:  2020-07

4.  Role of cantharidin in the activation of IKKα/IκBα/NF‑κB pathway by inhibiting PP2A activity in cholangiocarcinoma cell lines.

Authors:  Huijiang Zhou; Jiangfeng Xu; Shuai Wang; Jinfeng Peng
Journal:  Mol Med Rep       Date:  2018-04-05       Impact factor: 2.952

5.  Adrenal metastasis in sequentially developed combined hepatocellular carcinoma-cholangiocarcinoma: A case report.

Authors:  Adianto Nugroho; Kwang-Woong Lee; Kyung-Bun Lee; Hyo-Shin Kim; Hyeyoung Kim; Nam-Joon Yi; Kyung-Suk Suh
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2018-08-31

Review 6.  Combined Hepatocellular-Cholangiocarcinoma: An Update on Pathology and Diagnostic Approach.

Authors:  Joon Hyuk Choi; Jae Y Ro
Journal:  Biomedicines       Date:  2022-07-29

7.  Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma.

Authors:  Ming-Chun Ma; Yi-Ju Chen; Tai-Jan Chiu; Jui Lan; Chien-Ting Liu; Yi-Ching Chen; Hsin-Ho Tien; Yen-Yang Chen
Journal:  BMC Cancer       Date:  2018-02-27       Impact factor: 4.430

8.  Long-term outcome and prognostic factors of combined hepatocellular carcinoma and cholangiocarcinoma after curative resection.

Authors:  Xing-Xing Jiang; Xi-Tai Huang; Chen-Song Huang; Liu-Hua Chen; Li-Jian Liang; Xiao-Yu Yin
Journal:  Gastroenterol Rep (Oxf)       Date:  2020-03-13

9.  Effect of delta α-fetoprotein on the detection of liver cancer recurrence.

Authors:  Li-Yue Sun; Yuan He; Qing Liu; Fang Wang
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.